Diamond Hill Capital Management LLC Investment Advisor Takes Position in Boston Scientific Corporation $BSX

Diamond Hill Capital Management LLC Investment Advisor bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 157,829 shares of the medical equipment provider’s stock, valued at approximately $6,736,000.

Several other institutional investors have also modified their holdings of BSX. HBK Sorce Advisory LLC acquired a new position in Boston Scientific during the second quarter worth $402,000. Gould Asset Management LLC CA acquired a new stake in Boston Scientific in the second quarter valued at $445,000. J.Safra Asset Management Corp acquired a new stake in Boston Scientific in the second quarter valued at $45,000. Global Retirement Partners LLC purchased a new position in Boston Scientific during the 2nd quarter valued at about $1,609,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Boston Scientific during the 2nd quarter worth approximately $339,031,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BSX. Barclays cut their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Robert W. Baird set a $56.00 target price on Boston Scientific in a research report on Thursday, July 30th. TD Cowen reduced their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, Oppenheimer dropped their target price on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 27th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Stock Down 0.7%

NYSE:BSX opened at $51.46 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market capitalization of $74.58 billion, a price-to-earnings ratio of 20.83, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The stock has a 50-day simple moving average of $46.12 and a 200 day simple moving average of $58.81.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig bought 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 202,122 shares of company stock valued at $9,813,931. 0.34% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.